- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Sanofi and Regeneron report results from two Phase III trials of COPD treatment | ||
| Mo | ASCO25: MSD's KRAS G12C drug shows early promise in Phase I | ||
| Mo | ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles | ||
| Mo | CirCode Biomed gains clearance from FDA for RNA drug HM2002 | ||
| Mo | Zymeworks' zanidatamab gains approval in China for biliary tract cancer | ||
| 30.05. | ASCO25: Pfizer's Braftovi combo boasts 47% drop in disease progression in mCRC | ||
| 30.05. | EyePoint advances with Duravyu Phase III trial | ||
| 30.05. | Alvotech and Advanz to commercialise biosimilars in Europe | ||
| 30.05. | FDA rejects Stealth Bio's Barth syndrome treatment after 16.5-month review | ||
| 30.05. | Astellas and Evopoint sign ADC licensing deal | ||
| 30.05. | Daiichi Sankyo and MSD withdraw US application for lung cancer BLA | ||
| 29.05. | Solid tumours: CAR-T therapies' Waterloo | ||
| 29.05. | Regeneron to deploy Telesis Bio's Gibson SOLA at R&D facilities | ||
| 29.05. | iTeos to shut down following $2bn GSK-partnered TIGIT asset failure | ||
| 29.05. | FDA approves Eton's application for hydrocortisone oral solution | ||
| 29.05. | EC approves BMS' nivolumab SC formulation for solid tumours | ||
| 28.05. | FDA grants RMAT designation to AbelZeta's CAR-T therapy | ||
| 28.05. | 4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules | ||
| 28.05. | How 3PL providers are gearing up for the wave of cell and gene therapies | ||
| 28.05. | CDC drops Covid-19 vaccine for healthy children and pregnant women | ||
| 28.05. | GlycoEra secures $130m to progress IgG4-targeted protein degrader | ||
| 28.05. | Biogen and City Therapeutics to develop RNAi therapy | ||
| 27.05. | How the cell and gene therapy market is taking shape | ||
| 27.05. | Eli Lilly to expand pain pipeline with $1bn SiteOne buyout | ||
| 27.05. | Capitalising on UK's goal to become a world-leading clinical trial destination |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .